Daiichi Sankyo Company, Limited
Research Daiichi Sankyo Company, Limited (4568.T) on Bullrun: market cap JPY 4.99T, P/E 20.8, dividend yield 3.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4568.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyJPY
- Market capJPY 4.99T
- P/E20.8
- Dividend yield3.2%
- Financial periodFY2026
- RevenueJPY 2.12T
- Revenue growth12.6%
- Net incomeJPY 259.87B
- Free cash flow-JPY 71.35B
- Gross margin68.5%
Valuation Snapshot
latest market cap is JPY 4.99T; P/E is 20.8; dividend yield is 3.2%.
Peer valuation comparison
Latest P/E is 20.75x versus a Healthcare sector median of 21.69x (4.3% below).
Latest dividend yield is 3.16% versus a Healthcare sector median of 2.41% (31.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 2.12T | JPY 259.87B | -JPY 71.35B | 68.5% | 140.37 | JPY 449.81B | JPY 300.48B | JPY 1.66T |
| FY2025 | JPY 1.89T | JPY 295.76B | -JPY 134.03B | 78.0% | 155.87 | JPY 639.84B | JPY 101.33B | JPY 1.62T |
| FY2024 | JPY 1.60T | JPY 200.73B | JPY 476.47B | 74.1% | 104.62 | JPY 647.18B | JPY 101.71B | JPY 1.69T |
| FY2023 | JPY 1.28T | JPY 109.19B | JPY 47.15B | 71.6% | 56.91 | JPY 441.92B | JPY 143.09B | JPY 1.45T |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 4.99T | 20.8 | 3.7% | 100 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 100 JPY, yield 3.2%.
| Year | Dividends/share |
|---|---|
| FY2026 | 89 JPY |
| FY2025 | 69 JPY |
| FY2024 | 60 JPY |
| FY2023 | 35 JPY |
| FY2022 | 28.5 JPY |
About Daiichi Sankyo Company, Limited
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT;
ETFs that hold Daiichi Sankyo Company, Limited
Daiichi Sankyo Company, Limited is one of the ten largest holdings of 4 ETFs that investors in Europe can buy, most traded first:
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Daiichi Sankyo Company, Limited's market cap?
Daiichi Sankyo Company, Limited's market capitalization is JPY 4.99T.
What is Daiichi Sankyo Company, Limited's P/E ratio?
Daiichi Sankyo Company, Limited's price-to-earnings (P/E) ratio is 20.8.
Does Daiichi Sankyo Company, Limited pay a dividend?
Daiichi Sankyo Company, Limited has a dividend yield of 3.2%.
What does Daiichi Sankyo Company, Limited do?
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the.